Point-of-Care Technology Market Report 2025

The point-of-care technology market size has grown strongly in recent years. It will grow from $39.33 billion in 2024 to $43.21 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth observed during the historic period can be attributed to the increasing decentralization of healthcare delivery, rising demand for real-time diagnosis in emergencies, expanding need for rapid infection screening, growing deployment of mobile testing units, and an accelerating focus on cost-effective diagnostic workflows.

The point-of-care technology market size is expected to see strong growth in the next few years. It will grow to $62.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth projected for the forecast period can be attributed to the rising adoption of telemedicine platforms, growing emphasis on personalized and predictive care, expanding use in home-based health monitoring, and increasing government initiatives supporting decentralized testing. Key trends during this period include advancements in artificial intelligence-powered diagnostic algorithms, development of portable multiplex testing devices, innovations in wearable health monitoring tools, progress in cloud-based data integration, and the establishment of home-based telehealth ecosystems.

The rising prevalence of chronic illnesses is expected to drive significant growth in the point-of-care (POC) technology market. Chronic illnesses long-lasting conditions requiring continuous care are increasingly common due to sedentary lifestyles, which contribute to risk factors such as heart disease and diabetes. Point-of-care technology addresses these challenges by enabling rapid, on-site diagnostic testing in clinics, homes, or remote care settings. By providing real-time results, these technologies reduce treatment delays, improve patient monitoring, and enhance overall healthcare convenience. For example, in June 2024, the UK’s National Health Service reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, an 18% increase from 3,065,825 cases in 2022, highlighting the rising burden of chronic conditions and the resulting need for efficient diagnostic solutions.

Key players in the POC technology market are focusing on AI-powered diagnostic platforms to enhance accuracy, speed, and accessibility in disease detection. These platforms combine artificial intelligence with portable diagnostic devices to deliver real-time testing for critical conditions such as cancer. For instance, in February 2025, Avitia Inc., a Canada-based point-of-care diagnostics company, launched an AI-powered platform for rapid, on-site cancer testing. By integrating machine learning algorithms, the system allows healthcare providers to perform accurate screening outside traditional laboratories, reducing turnaround times, enabling early detection, and expanding access to underserved or remote populations.

In July 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, acquired the point-of-care platform from LumiraDx Group Limited for approximately $350 million. This acquisition allows Roche to expand its footprint in decentralized diagnostics by integrating a portable, user-friendly platform capable of immunochemistry and clinical chemistry testing, with future potential for molecular diagnostics. LumiraDx Group Limited, based in the UK, specializes in next-generation POC diagnostic technologies, making this partnership a strategic step toward accessible and efficient patient-centered care.

Major players in the point-of-care technology market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Hologic Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Cepheid Inc., Radiometer Medical ApS, Nova Biomedical, Sekisui Diagnostics LLC, Abaxis Inc., BHR Biosynex, EKF Diagnostics Holdings plc, Acon Laboratories Inc., Trinity Biotech plc, Chembio Diagnostics Inc., Arkray Inc., Orchard Software Corporation, Point of Care Biomedical Private Limited.

North America was the largest region in the point-of-care technology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in point-of-care technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the point-of-care technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Point-of-care technology refers to medical diagnostic devices and tools used at or near the site of patient care, including clinics, hospitals, or even homes. It provides rapid, accurate, and real-time diagnostic results, enabling timely clinical decisions and improving patient outcomes. This technology reduces reliance on centralized laboratory testing and accelerates the initiation of treatment.

The key types of point-of-care technology include diagnostic devices, monitoring devices, therapeutic devices, and data management systems. Diagnostic devices detect and identify diseases or health conditions by analyzing biological samples such as blood, saliva, or urine. These solutions are available under various models, including standalone, integrated, and cloud-based systems, and employ technologies such as microfluidics, polymerase chain reaction (PCR), and immunoassays. They are applied in areas including infectious disease testing, glucose monitoring, cardiometabolic monitoring, pregnancy and fertility testing, and more, serving end users such as hospitals, clinics, homecare settings, and ambulatory surgical centers.

The point-of-care technology market research report is one of a series of new reports that provides point-of-care technology market statistics, including point-of-care technology industry global market size, regional shares, competitors with a point-of-care technology market share, detailed point-of-care technology market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care technology industry. This point-of-care technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point-of-care technology market consists of revenues earned by entities by providing services such as rapid diagnostic testing, decentralized patient monitoring, emergency response diagnostics, and personalized treatment support. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care technology market also includes sales of handheld diagnostic devices, portable analyzers, lab-on-a-chip systems, digital test kits, and connected biosensors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.